ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials

Yang, Yuanming; Rao, Kehan; Zhan, Kai; Shen, Min; Zheng, Huan; Qin, Shumin; Wu, Haomeng; Bian, Zhaoxiang*; Huang, Shaogang*广东省人民医院; 广州中医药大学
Frontiers in Public Health2022-11-24DOI: 10.3389/fpubh.2022.1022145
5被引10阅读
引用收藏
分享

摘要

Background: Acupuncture and moxibustion have been widely used in the treatment of Irritable Bowel Syndrome (IBS). But the evidence that acupuncture and moxibustion for IBS reduction of symptom severity and abdominal pain, and improvement of quality of life is scarce.Methods: PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), Wanfang Database, China Biomedical Literature Service System (SinoMed), and unpublished sources were searched from inception until June 30, 2022. The quality of RCTs was assessed with the Cochrane Collaboration risk of bias tool. The strength of the evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation system (GRADE). Trial sequential analysis (TSA) was conducted to determine whether the participants in the included trials had reached optimal information size and whether the cumulative data was adequately powered to evaluate outcomes.Results: A total of 31 RCTs were included. Acupuncture helped reduce the severity of symptoms more than pharmaceutical drugs (MD, -35.45; 95% CI, -48.21 to -22.68; I-2 = 71%). TSA showed the cumulative Z score crossed O'Brien-Fleming alpha-spending significance boundaries. Acupuncture wasn't associated with symptom severity reduction (SMD, 0.03, 95% CI, -0.25 to 0.31, I-2 = 46%), but exhibited therapeutic benefits on abdominal pain (SMD, -0.24; 95% CI, -0.48 to -0.01; I-2 = 8%) compared to sham acupuncture. Moxibustion show therapeutic benefits compared to sham moxibustion on symptom severity (SMD, -3.46, 95% CI, -5.66 to -1.27, I-2 = 95%) and abdominal pain (SMD, -2.74, 95% CI, -4.81 to -0.67, I-2 = 96%). Acupuncture (SMD, -0.46; 95% CI, -0.68 to -0.24; I-2 = 47%) and the combination of acupuncture and moxibustion (SMD, -2.00; 95% CI, -3.04 to -0.96; I-2 = 90%) showed more benefit for abdominal pain compared to pharmacological medications as well as shams. Acupuncture (MD, 4.56; 95% CI, 1.46-7.67; I-2 = 79%) and moxibustion (MD, 6.97; 95% CI, 5.78-8.16; I-2 = 21%) were more likely to improve quality of life than pharmaceutical drugs.Conclusion: Acupuncture and/or moxibustion are beneficial for symptom severity, abdominal pain and quality of life in IBS. However, in sham control trials, acupuncture hasn't exhibited robust and stable evidence, and moxibustion's results show great heterogeneity. Hence, more rigorous sham control trials of acupuncture or moxibustion are necessary.Systematic review registration:https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=262118, identifier CRD42021262118

学科与关键词

关键词
irritable bowel syndromeacupuncturemoxibustioncomplementary and alternative medicineabdominal painquality of life
相关
加载中…
  • Analysis of Regularity of Acupuncture and Moxibustion in the Treatment of D-IBS and C-IBS by Data Mining
    郑桂芝; 李晗; 周次利; 包春辉; 张方; 王晓梅; 马喆; 窦传字; 马晓芃; 李璟; 吴焕淦世界中医药, 2017, 12(3).
  • Acupuncture and moxibustion for endometriosis: A systematic review and analysis
    Wang, Yongxia; Coyle, Meaghan E.; Hong, Miaowen; He, Siya; Zhang, Anthony L.; Guo, Xinfeng; Lu, Chuanjian; Xue, Charlie C. L.*; Liang, Xuefang*Complementary Therapies in Medicine, 2023, 76: 102963.被引 1
  • Acupoint application therapy for diarrhea-predominant irritable bowel syndrome: a protocol for systematic review and network meta-analysis
    Yin, Xinwei; Li, Shaowei; Ouyang, Minhua; Ou, Rui; Chen, Zhihuang; Wei, Song; Huang, Huai; Liu, Dandan*Annals of Palliative Medicine, 2022.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Public Health
发表日期
2022-11-24
卷期
第 10 卷
页码
1022145
DOI
10.3389/fpubh.2022.1022145
期刊等级
3区
成果收录
SSCI · SCIE
资助标注
National Natural Science Foundation of China [81974563, 81904148]; National Administration of Traditional Chinese Medicine of China [2019XZZX-XH002]; Guangdong Provincial Hospital of Chinese Medicine [YN10101907]; Basic and Applied Basic Research Projects of Guangzhou [202102010226, 202102010207]; Collaborative Innovation Team Project of Guangzhou University of Chinese Medicine [2021xk63]; Province Administration of Traditional Chinese Medicine of Guangdong [20192024, 20222074]; Young innovative talents project of general colleges and universities in Guangdong Province [2019KQNCX023]; Guangdong Medical Science and Technology Research Fund Project [A2020181]

作者

  • Y

    Yang, Yuanming (第一作者)

    guangzhou univ chinese med

  • R

    Rao, Kehan

    2 · guangzhou univ chinese med

查看全部 9 位作者收起作者
  • Z

    Zhan, Kai

    guangzhou univ chinese med

  • S

    Shen, Min

    shandong univ tradit chinese med

  • Z

    Zheng, Huan

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Q

    Qin, Shumin

    2 · guangdong prov hosp · guangzhou univ chinese med

  • W

    Wu, Haomeng

    2 · guangdong prov hosp · guangzhou univ chinese med

  • B

    Bian, Zhaoxiang (通讯)

    hong kong baptist univ

  • H

    Huang, Shaogang (通讯)

    guangzhou univ chinese med · 2 · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417